Scientists have reported encouraging early findings for an experimental Alzheimer’s drug that may help reduce brain damage linked to the disease, raising hopes for future treatments that target its underlying causes rather than only its symptoms.
The experimental medicine, KCL-286, demonstrated positive results in preclinical research by helping repair DNA damage in brain cells and reducing inflammation—two biological processes associated with the early stages of Alzheimer’s disease.
Study Highlights Promising Early Results
According to research published in the journal FEBS Open Bio, laboratory studies in mice showed that KCL-286 protected brain cells from damage while lowering inflammation.
Researchers said the findings suggest the drug could potentially slow the progression of Alzheimer’s disease if future clinical studies confirm its effectiveness.
Human Safety Trial Completed
Professor Jonathan Corcoran of King’s College London, a co-author of the study, said the drug has successfully completed a Phase 1 safety trial involving healthy volunteers.
He noted that the next step is to evaluate the treatment in Alzheimer’s patients, adding that funding—not scientific readiness—is currently the main obstacle to launching larger clinical trials.
Further Clinical Trials Still Needed
Researchers cautioned that the treatment remains experimental and has not yet been proven effective for Alzheimer’s patients.
They emphasized that larger clinical trials are necessary to determine the drug’s long-term safety and effectiveness before it can be considered for routine medical use.
Also Read :UK Plans to Ban High-Caffeine Energy Drink Sales to Children Under 16
Today's E-Paper